DrugPatentWatch Database Preview
« Back to Dashboard
The generic ingredient in MEKTOVI is binimetinib. One supplier is listed for this compound. Additional details are available on the binimetinib profile page.
Generic Entry Opportunity Date for 210498
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 210498
Profile for product number 001
|Approval Date:||Jun 27, 2018||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Jun 27, 2025|
|Regulatory Exclusivity Use:||ENCORAFENIB IS INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA-APPROVED TEST|
|Regulatory Exclusivity Expiration:||Jun 27, 2023|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||➤ Try a Free Trial||Patent Expiration:||Aug 27, 2030||Product Flag?||Substance Flag?||Delist Request?|
|Patented Use:||INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA|
Complete Access Available with Subscription